Single-allergen sublingual immunotherapy versus multi-allergen subcutaneous immunotherapy for children with allergic rhinitis

Abstract

It has always been controversial whether a single allergen performs better than multiple allergens in polysensitized patients during the allergen-specific immunotherapy. This study aimed to examine the clinical efficacy of single-allergen sublingual immunotherapy (SLIT) versus multi-allergen subcutaneous immunotherapy (SCIT) and to discover the change of the biomarker IL-4 after 1-year immunotherapy in polysensitized children aged 6–13 years with allergic rhinitis (AR) induced by house dust mites (HDMs). The AR polysensitized children (n=78) were randomly divided into two groups: SLIT group and SCIT group. Patients in the SLIT group sublingually received a single HDM extract and those in the SCIT group were subcutaneously given multiple-allergen extracts (HDM in combination with other clinically relevant allergen extracts). Before and 1 year after the allergen-specific immunotherapy (ASIT), the total nasal symptom scores (TNSS), total medication scores (TMS) and IL-4 levels in peripheral blood mononuclear cells (PBMCs) were compared respectively between the two groups. The results showed that the TNSS were greatly improved, and the TMS and IL-4 levels were significantly decreased after 1-year ASIT in both groups (SLIT group: P<0.001; SCIT group: P<0.001). There were no significant differences in any outcome measures between the two groups (for TNSS: P>0.05; for TMS: P>0.05; for IL-4 levels: P>0.05). It was concluded that the clinical efficacy of single-allergen SLIT is comparable with that of multi-allergen SCIT in 6–13-year-old children with HDM-induced AR.

Keywords

single allergen / sublingual immunotherapy / multi-allergen / subcutaneous immunotherapy / children / allergic rhinitis

References

[1] PinartM, KellerT, ReichA, et al. . Sex-related allergic rhinitis prevalence switch from childhood to adulthood: A systematic review and meta-analysis. Int Arch Allergy Immunol, 2017, 172(4): 224-235 PMID: 28456795

[2] ValentaR, CampanaR, Focke-TejklM, et al. . Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol, 2016, 137(2): 351-357 PMID: 26853127 PMCID: 4861208

[3] OzdemirC, KucuksezerUC, AkdisM, et al. . Mechanisms of aeroallergen immunotherapy: Subcutaneous immunotherapy and sublingual immunotherapy. Immunol Allergy Clin North Am, 2016, 36(1): 71-86 PMID: 26617228

[4] ArasiS, PassalacquaG, CaminitiL, et al. . Efficacy and safety of sublingual immunotherapy in children. Expert Rev Clin Immunol, 2016, 12(1): 49-56 PMID: 26496537

[5] DemolyP, OkamotoY, YangWH, et al. . 300 IR HDM tablet: a sublingual immunotherapy tablet for the treatment of house dust mite-associated allergic rhinitis. Expert Rev Clin Immunol, 2016, 12(11): 1141-1151 PMID: 27632814

[6] CanonicaGW, CoxL, PawankarR, et al. . Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J, 2014, 7(1): 6 PMID: 24679069 PMCID: 3983904

[7] ChelladuraiY, Suarez-CuervoC, ErekosimaN, et al. . Effectiveness of subcutaneous versus sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. J Allergy Clin Immunol Pract, 2013, 1(4): 361-369 PMID: 24565541

[8] EifanAO, AkkocT, YildizA, et al. . Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Immunol, 2010, 40(6): 922-932

[9] NelsonHS. Subcutaneous immunotherapy versus sublingual immunotherapy: which is more effective?. J Allergy Clin Immunol Pract, 2014, 2(2): 144-149 PMID: 24607040

[10] CalderónMA, CoxL, CasaleTB, et al. . Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol, 2012, 129(4): 929-934 PMID: 22244595

[11] BousquetJ, KhaltaevN, CruzAA, et al. . Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy, 2008, 63: 8-160 PMID: 18331513

[12] WangDH, ChenL, ChengL, et al. . Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled trial. Laryngoscope, 2013, 123(6): 1334-1340 PMID: 23616386

[13] PfaarO, DemolyP G v, WijkR, et al. . Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy, 2014, 69(7): 854-867 PMID: 24761804

[14] CoxL, LiJT, NelsonH, et al. . Allergen immunotherapy: a practice parameter second update. J Allergy Clin Immunol, 2007, 120(3): S25-S85

[15] SoyyigitS, GulogluD, IkinciogullariA, et al. . Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients. Ann Allergy Asthma Immunol, 2016, 116(3): 244-251 PMID: 26945497

[16] NonyE, MarteletA, JainK, et al. . Allergen extracts for immunotherapy: to mix or not to mix?. Expert Rev Clin Immunol, 2016, 9(3): 401-408

[17] AmarSM, HarbeckR J, SillsM, et al. . Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol, 2009, 124(1): 150-156 PMID: 19523672

[18] BéginP, NadeauKC. Epigenetic regulation of asthma and allergic disease. Allergy Asthma Clin Immunol, 2014, 10(1): 27 PMID: 24932182 PMCID: 4057652

[19] NaroznaB, HoffmannA, SobkowiakP, et al. . Polymorphisms in the interleukin 4, interleukin 4 receptor and interleukin 13 genes and allergic phenotype: A case control study. Adv Med Sci, 2016, 61(1): 40-45 PMID: 26426602

[20] CiprandiG, De AmiciM, MurdacaG, et al. . Serum IL-4 as a marker of immunological response to sublingual immunotherapy. J Biol Regul Homeost Agents, 2007, 22(2): 117-123

[21] LiP, LiQ, HuangZ, et al. . Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases. Int Forum Allergy Rhinol, 2014, 4(10): 796-801 PMID: 25145986